Member Info for Davemcmanus

Sally i did say if ever, but all depends on how the AIHL and future product ranges are rolled out, and if they hit a fraction of the numbers stated in the RNS.

Like i said though, it will be a good while if this EVER hits £1 again. With Budd's track record of delivery, i don't think they will do a good job of it. The amount he intends to raise via the placing says it all really. Who in their right mind will buy the super expensive POC test, or in material quantities anyway? £30 a test is beyond a joke. No business is goimg to be able to afford this, unless they pass on the costs to the customer which won't ho down well. Better stick to cheap LFTs. With regards to PCR like i said the other day the BC colloboration has done more damage than good here, since it made an already expensive test even more expensive by adding another 60% for their own margin. GDR's direct selling price at £10 was steep enough, however one could argue some labs would have been prepared to pay a slight premium due to the advantages of competitor products. But under Beckman the price shot up yo £16 a test, which had no chance.
Is anyone surprised they ain't sold a bean in the US?? Twice the price of FDA approved competitor products stood no chance, and even with FDA approval would have bern a push. Labs are not a charity are in to make money, and aren't going to lose margin that easily.

But will be longer than 12 months in my view, if ever.

It will linger here for a while depemding on how many placings shares are sold, and start to tick up once they are clearead imo. With regards to the business itself, I think the Covid angle is pretty much over for Genedrive, may get modrst sales if they are lucky but nothing of significance. The world has moved on and learned to live with Covid, and we are entering an era of LFTs which Genedrive don't have. AIIHL may come off, but don't expect it anytime soon. May see £1 here in 12 months or do if we are lucky.

Mik totally agree. They have £1.9 left on the bank and revisiting the launch costs for AIHL, they are going to be very minimal. AIHL took £600k to develop so can't be more than this to launch as a maximum, and same for POC. So lauch costs of around £1.2m combined, leaves behind £700k plus £10.5m from placing!!! Outrageous for Budd and Fowler to milk it for another few years. Hence PIs need to think carefully before taking place in the OO.

Some idiot on here yesterday suggested the OO was a sweetner for holders to get cheap shares. You can see the real motive behind it.

Not sure Pacman check the finer detail on google. It's an EGM you're looking for

Yes i'm invested now bugger off, no one has got time for your silly ramps. You've got yourself into a corner, and no wonder your ex wife is an ex after all, hardly surprising with your Intelligence

Just checked and a FTSE250 CFO gets £250k basic on average. Our Matt gets £180k for a zero revenue company!!!

Yes still can't understand why they have a full time CEO on £180k a year for a zero revenue company? FTSE250 Ceos get around £300k basic and they are mananging hundrefs of millions!!!

Yes it's called an EGM but think it needs to be initiated by holders with at least 5%

Oh Clark you're going to have to taje tge £ sigbs off thise binoculars. Unlike you Clark i don't give ny self a false sense of confidence, or try to be something i'm not. You now adnit it didn't sit right with you, but spent months mouthing off on here calling people Trolls, derampers etc...

*yet

It's right not erite Clarkster. Anyway It never sat right with you, get you were on here calling people paid trolls and derampers, whildt ramping away?? Hmmmm

Carlos i'd ignore Clarkster, check him out Twitter crying why he never sild but trying to give it the bigun on here. They were saying the sane in the 40s and it has dropped. What do you think people's imaginary buy in price is Clarky, 2p?

Pacman the devil is in the detail, it's obvious ("cover corporate expenses until AIHL and POC can cover operating expenses") he is raising enough cash to keep the lights on for a while without having to worry about sales. The can't need more than £1m for each launch, so £2m combined for the 2 launches leaves a healthy £8.5m in the bank. And yes his bonus last year was based on the cash position of the company and getting rid of the debt, which coincidentally PIs paid for via dilution. This year it'll probably be launching two new products and cash positive again.

Pacman i've said the same, down to everyone to make their own decisions. Do not take the open offer shares, buy on the market if you really want to average down. You're only doing further damage by participating in the OO, as well as giving Dudd an extra £4.5m for bonuses

Jay you need to read RNSs before topping up £20k. The trading update is in the RNS yesterday.

Stockid you still haven't learnt having the best product means naff all if you can't sell it. With Budd in charge those products are going no where. Just have a look at Universities world wide some impressive gadgets but are never commmervialised, and they move onto the next thing with their new research grant. This is exactly how Genedrive is operating, prove a concept and then move on. Just look at HCV test only one of it's kind, yet still failed to commercialise a hid problems with the product.

The problem with the BC colloboration was it made an already expensive test(£10) even more expensive with BC's margin it was closer to £16 a test which was also part of the problem.

Doozy- that's just an excuse, and you're believing just what DB wants you to believe. They could have made similar profits in Europe, just like Novacyt amongst others as an example. Nothing about the test was so specific about toward the USA market. It's clear there was no demand for the product, as it wasn't pushed hard enough.

Or Europe